Unal, G. Et Al. 2016. Famotidine: Is it a potential new candidate for the treatment of schizophrenia by inhibiting GSK-3 beta?. 29th Congress of the European-College-of-Neuropsychopharmacology (ECNP) , (Vienna, Austria).

Unal, G., DOKUMACI, A. H., Hazar-Yavuz, A. N., AYCAN, M. B., Sahin, C., Keles, R., ... Aricioglu, F.(2016). Famotidine: Is it a potential new candidate for the treatment of schizophrenia by inhibiting GSK-3 beta? . 29th Congress of the European-College-of-Neuropsychopharmacology (ECNP), Vienna, Austria

Unal, GÖKHAN Et Al. "Famotidine: Is it a potential new candidate for the treatment of schizophrenia by inhibiting GSK-3 beta?," 29th Congress of the European-College-of-Neuropsychopharmacology (ECNP), Vienna, Austria, 2016

Unal, GÖKHAN Et Al. "Famotidine: Is it a potential new candidate for the treatment of schizophrenia by inhibiting GSK-3 beta?." 29th Congress of the European-College-of-Neuropsychopharmacology (ECNP) , Vienna, Austria, 2016

Unal, G. Et Al. (2016) . "Famotidine: Is it a potential new candidate for the treatment of schizophrenia by inhibiting GSK-3 beta?." 29th Congress of the European-College-of-Neuropsychopharmacology (ECNP) , Vienna, Austria.

@conferencepaper{conferencepaper, author={GÖKHAN ÜNAL Et Al. }, title={Famotidine: Is it a potential new candidate for the treatment of schizophrenia by inhibiting GSK-3 beta?}, congress name={29th Congress of the European-College-of-Neuropsychopharmacology (ECNP)}, city={Vienna}, country={Austria}, year={2016}}